Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies
- Cancers (Basel). 2025 May 31;17(11):1853. doi: 10.3390/cancers17111853.
- 1. Surgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ 08103, USA.
- 2. Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
- 3. Coriell Institute for Medical Research, Camden, NJ 08103, USA.
- 4. Insilico Medicine Canada Inc., Montreal, QC H3B 4W8, Canada.
- 5. MD Anderson Cancer Center at Cooper, Camden, NJ 08103, USA.
The lethality of esophageal squamous cell carcinoma (ESCC), and Other epithelial cancers, is primarily due to its aggressive nature and frequent lymphatic metastasis, both of which impact prognosis. In this review, we explore the underlying molecular mechanisms of ESCC lymphatic metastasis, specifically, the functional role of NRF2 and therapeutic strategies. Current data suggest that NRF2 hyperactivation (NRF2high) may promote lymphatic metastasis of ESCC by affecting the extracellular matrix (ECM), epithelial-mesenchymal transition (EMT), lymphangiogenesis, immune evasion, metabolic programming, and Hippo signaling. We also update the latest developments in NRF2 inhibitors, their mechanisms of action, screening strategies, and approaches for evaluating compound efficacy. Finally, we highlight the utility of animal models for mechanistic studies and therapeutic development. We believe elucidation of the functional role of NRF2 in ESCC lymphatic metastasis and developing proper NRF2 inhibitors will greatly improve the clinical prognosis of ESCC in human patients.
-
Cat. No.Product NameDescriptionTargetResearch Area
-